Abstract
Overview
Introduction
Despite affecting a large number of individuals, there are currently no
treatments capable of curing either Parkinson's disease or Restless Legs
Syndrome. Although available treatments are effective, numerous unmet needs
prevail. Several compounds are in late-stage development and are forecast to
achieve sales of $519m for Parkinson's disease and $399m for Restless Legs
Syndrome in 2015.
Scope
- Analysis of patient potential, unmet needs and clinical trial design in
Parkinson's disease and Restless Legs Syndrome across the US, EU and Japan
- Overview of drugs in pre-registration, Phase III, II, I and preclinical
development; with analysis of key companies involved in the market
- Detailed profiles of key compounds in development for Parkinson's disease
and Restless Legs Syndrome, with forecasts of drug revenues to 2015
- Discussion of innovative early stage products and insight from key
industry opinion leaders
Highlights
Dopamine agonists with alternative delivery systems are expected to drive
near-term changes in the Parkinson's disease market. While Schwarz's
rotigotine patch holds several advantages over current oral treatments its
success looks set to be eclipsed by GSK's once-daily tablet, Requip Modutab,
which is forecast to reach peak sales of $543m in 2011.
The mid-stage pipeline for Parkinson's disease is unimpressive, with a host of
potential neuroprotectants failing to demonstrate conclusive benefits in
slowing disease progression. The most exciting near-term prospects are likely
to come from cell and gene therapy products such as Titan/Schering's
Spheramine or Avigen's AV-201.
The recent approval of the dopamine agonists Requip and Mirapex for Restless
Legs Syndrome have provided a viable treatment option. However, unmet needs
still exist and treatments, such as XenoPort's XP13512 which offer alternative
mechanisms to dopaminergic stimulation may provide greater symptomatic benefit
to current treatments.
Reasons to Purchase
- Understand unmet needs in the Parkinson's disease and Restless Legs
Syndrome market based on key opinion leader comments
- Benchmark key late-stage Parkinson's disease and Restless Legs Syndrome
compounds against current market leaders
- Assess the global sales forecasts of late-stage pipeline drugs; and
examine their clinical and commercial potential
| 
View Cart
